Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide.

Hegedűs ZI, Jakab ME, Gergely TG, Sayour NV, Kovács A, Antal S, Kovács T, Ferdinandy P, Varga ZV, Tóth VE

Cardiovascular diabetology14 Jun 2025Cited by 6 (Europe PMC)

PMID40517248PMCIDPMC12166642DOI10.1186/s12933-025-02806-5PepBankPUB-40517248

Summary

BackgroundIncretin analogues, used for the treatment of type 2 diabetes mellitus and obesity, such as GLP1-receptor agonist liraglutide (Lira) have been shown to reduce major adverse cardiac events in recent clinical trials of heart failure. Tirzepatide (TZP), a dual GIP/GLP1-receptor agonist has shown promising results in the SUMMIT trial as improved cardiovascular outcomes in patients with heart failure with preserved ejection fraction (HFpEF). However, data regarding their use in heart failure with reduced ejection fraction (HFrEF) is lacking. We performed a head-to-head comparative study in a mouse model of non-ischaemic cardiac injury induced by continuous angiotensin II (AngII) infusion, as AngII is a key driver of both heart failure forms.MethodsOsmotic minipumps were inserted for subcutaneous (s.c.) administration of AngII (1.5 mg/kg/day) in 5-month-old male Balb/c mice or sham surgery was performed. Animals were treated with vehicle (Veh), Lira (300 µg/day i.p.) or TZP (48 µg/day s.c.) for 14 days in the following groups: Sham/Veh (n = 7), AngII/Veh (n = 15), Sham/Lira (n = 7), AngII/Lira (n = 15), Sham/TZP (n = 8), AngII/TZP (n = 15). Cardiac structural, functional and molecular characteristics were assessed by echocardiography, ECG, immunohistochemistry, flow cytometry and qRT-PCR.ResultsMortality was significantly higher in AngII/Veh animals compared to controls, while AngII/TZP mice showed significantly reduced mortality after 14 days of treatment. Both Lira and TZP caused significant weight reduction compared to controls. AngII given alone also reduced body mass, and this reduction was further enhanced by TZP. Treatment with both compounds preserved cardiac systolic and diastolic function compared with AngII/Veh animals, as shown by normal ejection fraction and E/e', respectively. Both Lira and TZP decreased the AngII-induced elevation of cardiac fibrosis and hypertrophy markers, including Ctgf, Col1a1, Col3a1, and Nppa, while TZP also reduced the elevated Nppb level. TZP also reduced systemic inflammation, as shown by the reduction in serum CRP levels.ConclusionsLira and TZP preserved cardiac function and decreased markers of hypertrophy and fibrosis in mice with AngII-induced heart failure, whereas TZP also significantly decreased mortality. In addition to HFpEF, the use of incretin analogues may also be of clinical relevance in the treatment of HFrEF. However, as patients with heart failure, AngII level is elevated and can cause weight loss/cachexia, the usage of incretin analogues to treat non-obese heart failure patients should be considered.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study18

18 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In male Balb/c mice in a sham/AngII experiment, liraglutide reduced weight versus controls; the native result was not split by challenge and full-comparison analyzed N was unstated.
In plain wordsIn male Balb/c mice, liraglutide reduced weight versus controls; the sham/AngII subgroup and full comparison size were unspecified.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
mousen: not reported in source
Male Balb/c sham/AngII experiment; native weight result not split by challenge
Comparator
Controls; exact sham/AngII reference unstated
Outcome group
Body weight · Metabolic and weight
Studied dose
300 µg/day · intraperitoneal · 14 daysAs given in this study (mouse).
Source sentences
Summary
Both Lira and TZP caused significant weight reduction compared to controls.
3 context sentences(design, population, supporting numbers)
Summary · context
Osmotic minipumps were inserted for subcutaneous (s.c.) administration of AngII (1.5 mg/kg/day) in 5-month-old male Balb/c mice or sham surgery was performed.
Summary · context
Animals were treated with vehicle (Veh), Lira (300 µg/day i.p.) or TZP (48 µg/day s.c.) for 14 days in the following groups: Sham/Veh (n = 7), AngII/Veh (n = 15), Sham/Lira (n = 7), AngII/Lira (n = 15), Sham/TZP (n = 8), AngII/TZP (n = 15).
Summary · context
Cardiac structural, functional and molecular characteristics were assessed by echocardiography, ECG, immunohistochemistry, flow cytometry and qRT-PCR.
Show in the study text Report a problemFND-4051724801
02AnimalAnimal study (in vivo)Efficacy outcome
In male Balb/c AngII/TZP mice, tirzepatide reduced mortality after 14 days; the exact reduction reference and full-comparison analyzed N were unstated.
In plain wordsIn male Balb/c mice given AngII, tirzepatide reduced mortality; the exact comparison was unspecified.
Peptide
Tirzepatide
Outcome
DecreaseMortality
Study
mousen: not reported in source
angiotensin II-induced heart failure
Outcome group
Mortality · Whole body
Studied dose
48 µg/day · subcutaneous · 14 daysAs given in this study (mouse).
Source sentences
Summary
Mortality was significantly higher in AngII/Veh animals compared to controls, while AngII/TZP mice showed significantly reduced mortality after 14 days of treatment.
3 context sentences(design, population, supporting numbers)
Summary · context
Osmotic minipumps were inserted for subcutaneous (s.c.) administration of AngII (1.5 mg/kg/day) in 5-month-old male Balb/c mice or sham surgery was performed.
Summary · context
Animals were treated with vehicle (Veh), Lira (300 µg/day i.p.) or TZP (48 µg/day s.c.) for 14 days in the following groups: Sham/Veh (n = 7), AngII/Veh (n = 15), Sham/Lira (n = 7), AngII/Lira (n = 15), Sham/TZP (n = 8), AngII/TZP (n = 15).
Summary · context
Cardiac structural, functional and molecular characteristics were assessed by echocardiography, ECG, immunohistochemistry, flow cytometry and qRT-PCR.
Show in the study text Report a problemFND-4051724802
03AnimalAnimal study (in vivo)Efficacy outcome
In male Balb/c mice in a sham/AngII experiment, tirzepatide reduced weight versus controls; the native result was not split by challenge and full-comparison analyzed N was unstated.
In plain wordsIn male Balb/c mice, tirzepatide reduced weight versus controls; the sham/AngII subgroup and full comparison size were unspecified.
Peptide
Tirzepatide
Outcome
DecreaseBody weight
Study
mousen: not reported in source
Male Balb/c sham/AngII experiment; native weight result not split by challenge
Comparator
Controls; exact sham/AngII reference unstated
Outcome group
Body weight · Metabolic and weight
Studied dose
48 µg/day · subcutaneous · 14 daysAs given in this study (mouse).
Source sentences
Summary
Both Lira and TZP caused significant weight reduction compared to controls.
3 context sentences(design, population, supporting numbers)
Summary · context
Osmotic minipumps were inserted for subcutaneous (s.c.) administration of AngII (1.5 mg/kg/day) in 5-month-old male Balb/c mice or sham surgery was performed.
Summary · context
Animals were treated with vehicle (Veh), Lira (300 µg/day i.p.) or TZP (48 µg/day s.c.) for 14 days in the following groups: Sham/Veh (n = 7), AngII/Veh (n = 15), Sham/Lira (n = 7), AngII/Lira (n = 15), Sham/TZP (n = 8), AngII/TZP (n = 15).
Summary · context
Cardiac structural, functional and molecular characteristics were assessed by echocardiography, ECG, immunohistochemistry, flow cytometry and qRT-PCR.
Show in the study text Report a problemFND-4051724803
04AnimalAnimal study (in vivo)Efficacy outcome
In male Balb/c mice given AngII, tirzepatide further enhanced body-mass reduction compared with AngII alone; the coefficient and full-comparison analyzed N were unstated.
In plain wordsIn male Balb/c mice given AngII, tirzepatide further reduced body mass compared with AngII alone.
Peptide
Tirzepatide
Outcome
DecreaseBody mass reduction with angiotensin II
Study
mousen: not reported in source
angiotensin II-induced heart failure
Comparator
AngII given alone
Outcome group
Body weight · Metabolic and weight
Studied dose
48 µg/day · subcutaneous · 14 daysAs given in this study (mouse).
Source sentences
Summary
AngII given alone also reduced body mass, and this reduction was further enhanced by TZP.
3 context sentences(design, population, supporting numbers)
Summary · context
Osmotic minipumps were inserted for subcutaneous (s.c.) administration of AngII (1.5 mg/kg/day) in 5-month-old male Balb/c mice or sham surgery was performed.
Summary · context
Animals were treated with vehicle (Veh), Lira (300 µg/day i.p.) or TZP (48 µg/day s.c.) for 14 days in the following groups: Sham/Veh (n = 7), AngII/Veh (n = 15), Sham/Lira (n = 7), AngII/Lira (n = 15), Sham/TZP (n = 8), AngII/TZP (n = 15).
Summary · context
Cardiac structural, functional and molecular characteristics were assessed by echocardiography, ECG, immunohistochemistry, flow cytometry and qRT-PCR.
Show in the study text Report a problemFND-4051724804
05AnimalAnimal study (in vivo)Efficacy outcome
In male Balb/c AngII mice, liraglutide preserved systolic function versus AngII/Veh, described as normal ejection fraction; the signed numerical contrast and analyzed N were unstated.
In plain wordsIn male Balb/c AngII mice, liraglutide preserved systolic function versus vehicle; the signed numerical difference was unstated.
Peptide
Liraglutide
Outcome
Direction not reportedCardiac systolic function (ejection fraction)
Study
mousen: not reported in source
angiotensin II-induced heart failure
Comparator
AngII/Veh animals
Outcome group
Heart function · Cardiovascular
Studied dose
300 µg/day · intraperitoneal · 14 daysAs given in this study (mouse).
Source sentences
Summary
Treatment with both compounds preserved cardiac systolic and diastolic function compared with AngII/Veh animals, as shown by normal ejection fraction and E/e', respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Osmotic minipumps were inserted for subcutaneous (s.c.) administration of AngII (1.5 mg/kg/day) in 5-month-old male Balb/c mice or sham surgery was performed.
Summary · context
Animals were treated with vehicle (Veh), Lira (300 µg/day i.p.) or TZP (48 µg/day s.c.) for 14 days in the following groups: Sham/Veh (n = 7), AngII/Veh (n = 15), Sham/Lira (n = 7), AngII/Lira (n = 15), Sham/TZP (n = 8), AngII/TZP (n = 15).
Summary · context
Cardiac structural, functional and molecular characteristics were assessed by echocardiography, ECG, immunohistochemistry, flow cytometry and qRT-PCR.
Show in the study text Report a problemFND-4051724805
06AnimalAnimal study (in vivo)Efficacy outcome
In male Balb/c AngII mice, liraglutide preserved diastolic function versus AngII/Veh, described as normal E/e'; the signed numerical contrast and analyzed N were unstated.
In plain wordsIn male Balb/c AngII mice, liraglutide preserved diastolic function versus vehicle; the signed numerical difference was unstated.
Peptide
Liraglutide
Outcome
Direction not reportedCardiac diastolic function (E/e')
Study
mousen: not reported in source
angiotensin II-induced heart failure
Comparator
AngII/Veh animals
Outcome group
Heart function · Cardiovascular
Studied dose
300 µg/day · intraperitoneal · 14 daysAs given in this study (mouse).
Source sentences
Summary
Treatment with both compounds preserved cardiac systolic and diastolic function compared with AngII/Veh animals, as shown by normal ejection fraction and E/e', respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Osmotic minipumps were inserted for subcutaneous (s.c.) administration of AngII (1.5 mg/kg/day) in 5-month-old male Balb/c mice or sham surgery was performed.
Summary · context
Animals were treated with vehicle (Veh), Lira (300 µg/day i.p.) or TZP (48 µg/day s.c.) for 14 days in the following groups: Sham/Veh (n = 7), AngII/Veh (n = 15), Sham/Lira (n = 7), AngII/Lira (n = 15), Sham/TZP (n = 8), AngII/TZP (n = 15).
Summary · context
Cardiac structural, functional and molecular characteristics were assessed by echocardiography, ECG, immunohistochemistry, flow cytometry and qRT-PCR.
Show in the study text Report a problemFND-4051724806
07AnimalAnimal study (in vivo)Efficacy outcome
In male Balb/c AngII mice, tirzepatide preserved systolic function versus AngII/Veh, described as normal ejection fraction; the signed numerical contrast and analyzed N were unstated.
In plain wordsIn male Balb/c AngII mice, tirzepatide preserved systolic function versus vehicle; the signed numerical difference was unstated.
Peptide
Tirzepatide
Outcome
Direction not reportedCardiac systolic function (ejection fraction)
Study
mousen: not reported in source
angiotensin II-induced heart failure
Comparator
AngII/Veh animals
Outcome group
Heart function · Cardiovascular
Studied dose
48 µg/day · subcutaneous · 14 daysAs given in this study (mouse).
Source sentences
Summary
Treatment with both compounds preserved cardiac systolic and diastolic function compared with AngII/Veh animals, as shown by normal ejection fraction and E/e', respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Osmotic minipumps were inserted for subcutaneous (s.c.) administration of AngII (1.5 mg/kg/day) in 5-month-old male Balb/c mice or sham surgery was performed.
Summary · context
Animals were treated with vehicle (Veh), Lira (300 µg/day i.p.) or TZP (48 µg/day s.c.) for 14 days in the following groups: Sham/Veh (n = 7), AngII/Veh (n = 15), Sham/Lira (n = 7), AngII/Lira (n = 15), Sham/TZP (n = 8), AngII/TZP (n = 15).
Summary · context
Cardiac structural, functional and molecular characteristics were assessed by echocardiography, ECG, immunohistochemistry, flow cytometry and qRT-PCR.
Show in the study text Report a problemFND-4051724807
08AnimalAnimal study (in vivo)Efficacy outcome
In male Balb/c AngII mice, tirzepatide preserved diastolic function versus AngII/Veh, described as normal E/e'; the signed numerical contrast and analyzed N were unstated.
In plain wordsIn male Balb/c AngII mice, tirzepatide preserved diastolic function versus vehicle; the signed numerical difference was unstated.
Peptide
Tirzepatide
Outcome
Direction not reportedCardiac diastolic function (E/e')
Study
mousen: not reported in source
angiotensin II-induced heart failure
Comparator
AngII/Veh animals
Outcome group
Heart function · Cardiovascular
Studied dose
48 µg/day · subcutaneous · 14 daysAs given in this study (mouse).
Source sentences
Summary
Treatment with both compounds preserved cardiac systolic and diastolic function compared with AngII/Veh animals, as shown by normal ejection fraction and E/e', respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Osmotic minipumps were inserted for subcutaneous (s.c.) administration of AngII (1.5 mg/kg/day) in 5-month-old male Balb/c mice or sham surgery was performed.
Summary · context
Animals were treated with vehicle (Veh), Lira (300 µg/day i.p.) or TZP (48 µg/day s.c.) for 14 days in the following groups: Sham/Veh (n = 7), AngII/Veh (n = 15), Sham/Lira (n = 7), AngII/Lira (n = 15), Sham/TZP (n = 8), AngII/TZP (n = 15).
Summary · context
Cardiac structural, functional and molecular characteristics were assessed by echocardiography, ECG, immunohistochemistry, flow cytometry and qRT-PCR.
Show in the study text Report a problemFND-4051724808
09AnimalAnimal study (in vivo)Efficacy outcome
In male Balb/c AngII mice, liraglutide reduced elevated Ctgf; the exact native comparison reference, coefficient and analyzed N were unstated.
In plain wordsIn male Balb/c AngII mice, liraglutide reduced elevated Ctgf; the exact comparison was unspecified.
Peptide
Liraglutide
Outcome
DecreaseCtgf marker
Study
mousen: not reported in source
angiotensin II-induced heart failure
Outcome group
Heart function · Cardiovascular
Studied dose
300 µg/day · intraperitoneal · 14 daysAs given in this study (mouse).
Source sentences
Summary
Both Lira and TZP decreased the AngII-induced elevation of cardiac fibrosis and hypertrophy markers, including Ctgf, Col1a1, Col3a1, and Nppa, while TZP also reduced the elevated Nppb level.
3 context sentences(design, population, supporting numbers)
Summary · context
Osmotic minipumps were inserted for subcutaneous (s.c.) administration of AngII (1.5 mg/kg/day) in 5-month-old male Balb/c mice or sham surgery was performed.
Summary · context
Animals were treated with vehicle (Veh), Lira (300 µg/day i.p.) or TZP (48 µg/day s.c.) for 14 days in the following groups: Sham/Veh (n = 7), AngII/Veh (n = 15), Sham/Lira (n = 7), AngII/Lira (n = 15), Sham/TZP (n = 8), AngII/TZP (n = 15).
Summary · context
Cardiac structural, functional and molecular characteristics were assessed by echocardiography, ECG, immunohistochemistry, flow cytometry and qRT-PCR.
Show in the study text Report a problemFND-4051724809
10AnimalAnimal study (in vivo)Efficacy outcome
In male Balb/c AngII mice, liraglutide reduced elevated Col1a1; the exact native comparison reference, coefficient and analyzed N were unstated.
In plain wordsIn male Balb/c AngII mice, liraglutide reduced elevated Col1a1; the exact comparison was unspecified.
Peptide
Liraglutide
Outcome
DecreaseCol1a1 marker
Study
mousen: not reported in source
angiotensin II-induced heart failure
Outcome group
Heart function · Cardiovascular
Studied dose
300 µg/day · intraperitoneal · 14 daysAs given in this study (mouse).
Source sentences
Summary
Both Lira and TZP decreased the AngII-induced elevation of cardiac fibrosis and hypertrophy markers, including Ctgf, Col1a1, Col3a1, and Nppa, while TZP also reduced the elevated Nppb level.
3 context sentences(design, population, supporting numbers)
Summary · context
Osmotic minipumps were inserted for subcutaneous (s.c.) administration of AngII (1.5 mg/kg/day) in 5-month-old male Balb/c mice or sham surgery was performed.
Summary · context
Animals were treated with vehicle (Veh), Lira (300 µg/day i.p.) or TZP (48 µg/day s.c.) for 14 days in the following groups: Sham/Veh (n = 7), AngII/Veh (n = 15), Sham/Lira (n = 7), AngII/Lira (n = 15), Sham/TZP (n = 8), AngII/TZP (n = 15).
Summary · context
Cardiac structural, functional and molecular characteristics were assessed by echocardiography, ECG, immunohistochemistry, flow cytometry and qRT-PCR.
Show in the study text Report a problemFND-4051724810
11AnimalAnimal study (in vivo)Efficacy outcome
In male Balb/c AngII mice, liraglutide reduced elevated Col3a1; the exact native comparison reference, coefficient and analyzed N were unstated.
In plain wordsIn male Balb/c AngII mice, liraglutide reduced elevated Col3a1; the exact comparison was unspecified.
Peptide
Liraglutide
Outcome
DecreaseCol3a1 marker
Study
mousen: not reported in source
angiotensin II-induced heart failure
Outcome group
Heart function · Cardiovascular
Studied dose
300 µg/day · intraperitoneal · 14 daysAs given in this study (mouse).
Source sentences
Summary
Both Lira and TZP decreased the AngII-induced elevation of cardiac fibrosis and hypertrophy markers, including Ctgf, Col1a1, Col3a1, and Nppa, while TZP also reduced the elevated Nppb level.
3 context sentences(design, population, supporting numbers)
Summary · context
Osmotic minipumps were inserted for subcutaneous (s.c.) administration of AngII (1.5 mg/kg/day) in 5-month-old male Balb/c mice or sham surgery was performed.
Summary · context
Animals were treated with vehicle (Veh), Lira (300 µg/day i.p.) or TZP (48 µg/day s.c.) for 14 days in the following groups: Sham/Veh (n = 7), AngII/Veh (n = 15), Sham/Lira (n = 7), AngII/Lira (n = 15), Sham/TZP (n = 8), AngII/TZP (n = 15).
Summary · context
Cardiac structural, functional and molecular characteristics were assessed by echocardiography, ECG, immunohistochemistry, flow cytometry and qRT-PCR.
Show in the study text Report a problemFND-4051724811
12AnimalAnimal study (in vivo)Efficacy outcome
In male Balb/c AngII mice, liraglutide reduced elevated Nppa; the exact native comparison reference, coefficient and analyzed N were unstated.
In plain wordsIn male Balb/c AngII mice, liraglutide reduced elevated Nppa; the exact comparison was unspecified.
Peptide
Liraglutide
Outcome
DecreaseNppa marker
Study
mousen: not reported in source
angiotensin II-induced heart failure
Outcome group
Heart function · Cardiovascular
Studied dose
300 µg/day · intraperitoneal · 14 daysAs given in this study (mouse).
Source sentences
Summary
Both Lira and TZP decreased the AngII-induced elevation of cardiac fibrosis and hypertrophy markers, including Ctgf, Col1a1, Col3a1, and Nppa, while TZP also reduced the elevated Nppb level.
3 context sentences(design, population, supporting numbers)
Summary · context
Osmotic minipumps were inserted for subcutaneous (s.c.) administration of AngII (1.5 mg/kg/day) in 5-month-old male Balb/c mice or sham surgery was performed.
Summary · context
Animals were treated with vehicle (Veh), Lira (300 µg/day i.p.) or TZP (48 µg/day s.c.) for 14 days in the following groups: Sham/Veh (n = 7), AngII/Veh (n = 15), Sham/Lira (n = 7), AngII/Lira (n = 15), Sham/TZP (n = 8), AngII/TZP (n = 15).
Summary · context
Cardiac structural, functional and molecular characteristics were assessed by echocardiography, ECG, immunohistochemistry, flow cytometry and qRT-PCR.
Show in the study text Report a problemFND-4051724812
13AnimalAnimal study (in vivo)Efficacy outcome
In male Balb/c AngII mice, tirzepatide reduced elevated Ctgf; the exact native comparison reference, coefficient and analyzed N were unstated.
In plain wordsIn male Balb/c AngII mice, tirzepatide reduced elevated Ctgf; the exact comparison was unspecified.
Peptide
Tirzepatide
Outcome
DecreaseCtgf marker
Study
mousen: not reported in source
angiotensin II-induced heart failure
Outcome group
Heart function · Cardiovascular
Studied dose
48 µg/day · subcutaneous · 14 daysAs given in this study (mouse).
Source sentences
Summary
Both Lira and TZP decreased the AngII-induced elevation of cardiac fibrosis and hypertrophy markers, including Ctgf, Col1a1, Col3a1, and Nppa, while TZP also reduced the elevated Nppb level.
3 context sentences(design, population, supporting numbers)
Summary · context
Osmotic minipumps were inserted for subcutaneous (s.c.) administration of AngII (1.5 mg/kg/day) in 5-month-old male Balb/c mice or sham surgery was performed.
Summary · context
Animals were treated with vehicle (Veh), Lira (300 µg/day i.p.) or TZP (48 µg/day s.c.) for 14 days in the following groups: Sham/Veh (n = 7), AngII/Veh (n = 15), Sham/Lira (n = 7), AngII/Lira (n = 15), Sham/TZP (n = 8), AngII/TZP (n = 15).
Summary · context
Cardiac structural, functional and molecular characteristics were assessed by echocardiography, ECG, immunohistochemistry, flow cytometry and qRT-PCR.
Show in the study text Report a problemFND-4051724813
14AnimalAnimal study (in vivo)Efficacy outcome
In male Balb/c AngII mice, tirzepatide reduced elevated Col1a1; the exact native comparison reference, coefficient and analyzed N were unstated.
In plain wordsIn male Balb/c AngII mice, tirzepatide reduced elevated Col1a1; the exact comparison was unspecified.
Peptide
Tirzepatide
Outcome
DecreaseCol1a1 marker
Study
mousen: not reported in source
angiotensin II-induced heart failure
Outcome group
Heart function · Cardiovascular
Studied dose
48 µg/day · subcutaneous · 14 daysAs given in this study (mouse).
Source sentences
Summary
Both Lira and TZP decreased the AngII-induced elevation of cardiac fibrosis and hypertrophy markers, including Ctgf, Col1a1, Col3a1, and Nppa, while TZP also reduced the elevated Nppb level.
3 context sentences(design, population, supporting numbers)
Summary · context
Osmotic minipumps were inserted for subcutaneous (s.c.) administration of AngII (1.5 mg/kg/day) in 5-month-old male Balb/c mice or sham surgery was performed.
Summary · context
Animals were treated with vehicle (Veh), Lira (300 µg/day i.p.) or TZP (48 µg/day s.c.) for 14 days in the following groups: Sham/Veh (n = 7), AngII/Veh (n = 15), Sham/Lira (n = 7), AngII/Lira (n = 15), Sham/TZP (n = 8), AngII/TZP (n = 15).
Summary · context
Cardiac structural, functional and molecular characteristics were assessed by echocardiography, ECG, immunohistochemistry, flow cytometry and qRT-PCR.
Show in the study text Report a problemFND-4051724814
15AnimalAnimal study (in vivo)Efficacy outcome
In male Balb/c AngII mice, tirzepatide reduced elevated Col3a1; the exact native comparison reference, coefficient and analyzed N were unstated.
In plain wordsIn male Balb/c AngII mice, tirzepatide reduced elevated Col3a1; the exact comparison was unspecified.
Peptide
Tirzepatide
Outcome
DecreaseCol3a1 marker
Study
mousen: not reported in source
angiotensin II-induced heart failure
Outcome group
Heart function · Cardiovascular
Studied dose
48 µg/day · subcutaneous · 14 daysAs given in this study (mouse).
Source sentences
Summary
Both Lira and TZP decreased the AngII-induced elevation of cardiac fibrosis and hypertrophy markers, including Ctgf, Col1a1, Col3a1, and Nppa, while TZP also reduced the elevated Nppb level.
3 context sentences(design, population, supporting numbers)
Summary · context
Osmotic minipumps were inserted for subcutaneous (s.c.) administration of AngII (1.5 mg/kg/day) in 5-month-old male Balb/c mice or sham surgery was performed.
Summary · context
Animals were treated with vehicle (Veh), Lira (300 µg/day i.p.) or TZP (48 µg/day s.c.) for 14 days in the following groups: Sham/Veh (n = 7), AngII/Veh (n = 15), Sham/Lira (n = 7), AngII/Lira (n = 15), Sham/TZP (n = 8), AngII/TZP (n = 15).
Summary · context
Cardiac structural, functional and molecular characteristics were assessed by echocardiography, ECG, immunohistochemistry, flow cytometry and qRT-PCR.
Show in the study text Report a problemFND-4051724815
16AnimalAnimal study (in vivo)Efficacy outcome
In male Balb/c AngII mice, tirzepatide reduced elevated Nppa; the exact native comparison reference, coefficient and analyzed N were unstated.
In plain wordsIn male Balb/c AngII mice, tirzepatide reduced elevated Nppa; the exact comparison was unspecified.
Peptide
Tirzepatide
Outcome
DecreaseNppa marker
Study
mousen: not reported in source
angiotensin II-induced heart failure
Outcome group
Heart function · Cardiovascular
Studied dose
48 µg/day · subcutaneous · 14 daysAs given in this study (mouse).
Source sentences
Summary
Both Lira and TZP decreased the AngII-induced elevation of cardiac fibrosis and hypertrophy markers, including Ctgf, Col1a1, Col3a1, and Nppa, while TZP also reduced the elevated Nppb level.
3 context sentences(design, population, supporting numbers)
Summary · context
Osmotic minipumps were inserted for subcutaneous (s.c.) administration of AngII (1.5 mg/kg/day) in 5-month-old male Balb/c mice or sham surgery was performed.
Summary · context
Animals were treated with vehicle (Veh), Lira (300 µg/day i.p.) or TZP (48 µg/day s.c.) for 14 days in the following groups: Sham/Veh (n = 7), AngII/Veh (n = 15), Sham/Lira (n = 7), AngII/Lira (n = 15), Sham/TZP (n = 8), AngII/TZP (n = 15).
Summary · context
Cardiac structural, functional and molecular characteristics were assessed by echocardiography, ECG, immunohistochemistry, flow cytometry and qRT-PCR.
Show in the study text Report a problemFND-4051724816
17AnimalAnimal study (in vivo)Efficacy outcome
In male Balb/c AngII mice, tirzepatide reduced elevated Nppb; the exact native comparison reference, coefficient and analyzed N were unstated.
In plain wordsIn male Balb/c AngII mice, tirzepatide reduced elevated Nppb; the exact comparison was unspecified.
Peptide
Tirzepatide
Outcome
DecreaseNppb marker
Study
mousen: not reported in source
angiotensin II-induced heart failure
Outcome group
Heart function · Cardiovascular
Studied dose
48 µg/day · subcutaneous · 14 daysAs given in this study (mouse).
Source sentences
Summary
Both Lira and TZP decreased the AngII-induced elevation of cardiac fibrosis and hypertrophy markers, including Ctgf, Col1a1, Col3a1, and Nppa, while TZP also reduced the elevated Nppb level.
3 context sentences(design, population, supporting numbers)
Summary · context
Osmotic minipumps were inserted for subcutaneous (s.c.) administration of AngII (1.5 mg/kg/day) in 5-month-old male Balb/c mice or sham surgery was performed.
Summary · context
Animals were treated with vehicle (Veh), Lira (300 µg/day i.p.) or TZP (48 µg/day s.c.) for 14 days in the following groups: Sham/Veh (n = 7), AngII/Veh (n = 15), Sham/Lira (n = 7), AngII/Lira (n = 15), Sham/TZP (n = 8), AngII/TZP (n = 15).
Summary · context
Cardiac structural, functional and molecular characteristics were assessed by echocardiography, ECG, immunohistochemistry, flow cytometry and qRT-PCR.
Show in the study text Report a problemFND-4051724817
18AnimalAnimal study (in vivo)Efficacy outcome
In male Balb/c AngII mice, tirzepatide reduced serum CRP as a systemic-inflammation marker; the exact comparison reference, coefficient and analyzed N were unstated.
In plain wordsIn male Balb/c AngII mice, tirzepatide reduced serum CRP; the exact comparison was unspecified.
Peptide
Tirzepatide
Outcome
DecreaseSerum C-reactive protein
Study
mousen: not reported in source
angiotensin II-induced heart failure
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
48 µg/day · subcutaneous · 14 daysAs given in this study (mouse).
Source sentences
Summary
TZP also reduced systemic inflammation, as shown by the reduction in serum CRP levels.
3 context sentences(design, population, supporting numbers)
Summary · context
Osmotic minipumps were inserted for subcutaneous (s.c.) administration of AngII (1.5 mg/kg/day) in 5-month-old male Balb/c mice or sham surgery was performed.
Summary · context
Animals were treated with vehicle (Veh), Lira (300 µg/day i.p.) or TZP (48 µg/day s.c.) for 14 days in the following groups: Sham/Veh (n = 7), AngII/Veh (n = 15), Sham/Lira (n = 7), AngII/Lira (n = 15), Sham/TZP (n = 8), AngII/TZP (n = 15).
Summary · context
Cardiac structural, functional and molecular characteristics were assessed by echocardiography, ECG, immunohistochemistry, flow cytometry and qRT-PCR.
Show in the study text Report a problemFND-4051724818

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:07 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide.

Summary

Results from this study18

Version history

Subjects

Publication types

MeSH terms

Keywords